Literature DB >> 28384883

Dasatinib Induced Cardiac Tamponade-A Rare Association.

Sushant Wattal1, Mugula Sudhakar Rao1, Gs Naveen Chandra2, U K Abdul Razak2, K Ranjan Shetty3.   

Abstract

Drug induced cardiac tamponade is rare. Therapy for imatinib resistant Chronic Myeloid Leukaemia (CML) is an emerging challenge in clinical haematology. For such cases treatment with second line tyrosine kinase inhibitors like dasatinib has resulted in improved outcomes. Dasatinib is a second line BCR-ABL tyrosine kinase inhibitor used in the treatment of Imatinib resistant or Imatinib intolerant CML. Dasatinib has been reported to cause severe pericardial effusions in 1% of all patients in clinical studies. We report here a case of Dasatinib induced cardiac tamponade in whom all other causes of pericardial effusion were excluded and whose clinical symptoms as well as effusion showed no recurrence one month after the drug was stopped.

Entities:  

Keywords:  Chronic myeloid leukaemia; Pericardial effusion; Tyrosine kinase inhibitor

Year:  2017        PMID: 28384883      PMCID: PMC5376847          DOI: 10.7860/JCDR/2017/24633.9418

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

1.  New tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  Giovanni Martinelli; Simona Soverini; Gianantonio Rosti; Daniela Cilloni; Michele Baccarani
Journal:  Haematologica       Date:  2005-04       Impact factor: 9.941

2.  Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

Authors:  Maria-Theresa Krauth; Susanne Herndlhofer; Maria-Theresa Schmook; Gerlinde Mitterbauer-Hohendanner; Ernst Schlögl; Peter Valent
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

3.  Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Authors:  S Mustjoki; M Ekblom; T P Arstila; I Dybedal; P K Epling-Burnette; F Guilhot; H Hjorth-Hansen; M Höglund; P Kovanen; T Laurinolli; J Liesveld; R Paquette; J Pinilla-Ibarz; A Rauhala; N Shah; B Simonsson; M Sinisalo; J L Steegmann; L Stenke; K Porkka
Journal:  Leukemia       Date:  2009-03-19       Impact factor: 11.528

Review 4.  Management of drug toxicities in chronic myeloid leukaemia.

Authors:  Michael J Mauro; Michael W Deininger
Journal:  Best Pract Res Clin Haematol       Date:  2009-09       Impact factor: 3.020

5.  Cardiac tamponade by loculated pericardial hematoma: limitations of M-mode echocardiography.

Authors:  I Kronzon; M L Cohen; H E Winer
Journal:  J Am Coll Cardiol       Date:  1983-03       Impact factor: 24.094

Review 6.  Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.

Authors:  Peter Valent
Journal:  Br J Haematol       Date:  2008-06-05       Impact factor: 6.998

Review 7.  New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Stefano Ulisciani; Marco Bosa; Daniela Cilloni; Giovanna Rege-Cambrin
Journal:  Leuk Lymphoma       Date:  2008-04

8.  Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.

Authors:  C Sillaber; H Herrmann; K Bennett; U Rix; C Baumgartner; A Böhm; S Herndlhofer; E Tschachler; G Superti-Furga; U Jäger; P Valent
Journal:  Eur J Clin Invest       Date:  2009-09-09       Impact factor: 4.686

Review 9.  The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Authors:  David Masiello; Gerry Gorospe; Allen S Yang
Journal:  J Hematol Oncol       Date:  2009-11-12       Impact factor: 17.388

Review 10.  Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Authors:  Kevin Kelly; Ronan Swords; Devalingam Mahalingam; Swaminathan Padmanabhan; Francis J Giles
Journal:  Target Oncol       Date:  2009-04-21       Impact factor: 4.493

  10 in total
  1 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.